Implantation of A Myval Octacor Aortic Valve in the Pulmonary Position Secondary to Combined Pulmonary Valve Disease Due to Severe Subvalvular Stenosis and Moderate Regurgitation: Case Report
Main Article Content
Abstract
Pulmonary stenosis is a congenital heart disease that may occur in isolation or in association with conditions such as Tetralogy of Fallot and Noonan Syndrome. It may be located at the valvular, subvalvular, or supravalvular level and is classified as mild, moderate, or severe according to the obstructive gradient. As the disease progresses, it may lead to right ventricular failure, dyspnea, syncope, and systemic congestion. Pulmonary regurgitation is usually secondary to pulmonary hypertension or surgically corrected congenital heart diseases, resulting in volume overload and deterioration of right ventricular function. Diagnosis is primarily established by echocardiography, complemented by cardiac magnetic resonance imaging and cardiac computed tomography. Percutaneous treatment with transcatheter valves, such as Melody, Harmony, and Edwards SAPIEN, has demonstrated improvement in symptoms, reduction of pulmonary regurgitation, and preservation of right ventricular function, although appropriate anatomical selection is required due to the risk of complications.
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Heaton J, Horenstein MS, Kyriakopoulos C. Pulmonary Stenosis. [Updated 2024 Oct 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www-ncbi-nlm-nih-gov.translate.goog/books/NBK560750/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
II. Goldstein, B. H., McElhinney, D. B., Gillespie, M. J., Aboulhosn, J. A., Levi, D. S., Morray, B. H., Cabalka, A. K., Love, B. A., Zampi, J. D., Balzer, D. T., Law, M. A., Schiff, M. D., Hoskoppal, A., & Qureshi, A. M. (2024). Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry. Journal Of The American College Of Cardiology, 83(14), 1310-1321. https://doi.org/10.1016/j.jacc.2024.02.010
III. Gillespie, M, McElhinney, D, Jones, T. et al. 1-Year Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Clinical Trial Participants. J Am Coll Cardiol Intv. 2023 Aug, 16 (15) 1917–1928
IV. Flores-Umanzor, E., Alshehri, B., Keshvara, R., Wilson, W., Osten, M., Benson, L., Abrahamyan, L., & Horlick, E. (2024). Transcatheter-Based Interventions for Tetralogy of Fallot Across All Age Groups. JACC: Cardiovascular Interventions, 17(9), 1079-1090. https://doi.org/10.1016/j.jcin.2024.02.009
V. Baumbach A, van Royen N, Amat-Santos IJ, Hudec M, Bunc M, Ijsselmuiden A, Laanmets P, Unic D, Merkely B, Hermanides RS, Ninios V, Protasiewicz M, Rensing BJWM, Martin PL, Feres F, De Sousa Almeida M, van Belle E, Linke A, Ielasi A, Montorfano M, Webster M, Toutouzas K, Teiger E, Bedogni F, Voskuil M, Pan M, Angerås O, Kim WK, Rothe J, Kristić I, Peral V, Garg S, Elzomor H, Tobe A, Morice MC, Onuma Y, Soliman O, Serruys PW; LANDMARK trial investigators. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial. Lancet. 2024 Jun 22;403(10445):2695-2708. doi: 10.1016/S0140-6736(24)00821-3. Epub 2024 May 22. Erratum in: Lancet. 2024 Jun 22;403(10445):2694. doi: 10.1016/S0140-6736(24)01259-5. Erratum in: Lancet. 2025 Mar 1;405(10480):700. doi: 10.1016/S0140-6736(25)00353-8. PMID: 38795719.
VI. Mittal S. Isolated infundibular pulmonary stenosis. Journal Of Clinical And Preventive Cardiology [Internet]. 1 de enero de 2018;7(4):154. Disponible en: https://doi.org/10.4103/jcpc.jcpc_18_18
VII. Marchini F, Meossi S, Passarini G, Campo G, Pavasini R. Pulmonary Valve Stenosis: From Diagnosis to Current Management Techniques and Future Prospects. Vascular Health And Risk Management [Internet]. 1 de junio de 2023;Volume 19:379-90. Disponible en: https://doi.org/10.2147/vhrm.s380240
VIII. Agasthi P, Saji AM, Sharma S. Regurgitación pulmonar. [Actualizado el 8 de enero de 2024]. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; enero de 2026-. Disponible en: https://www-ncbi-nlm-nih gov.translate.goog/books/NBK557564/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
IX. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007). Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation. New England Journal Of Medicine, 356(1), 29-38. https://doi.org/10.1056/nejmoa062222
X. Lee, Y., & Lee, H. (2012). Percutaneous pulmonary valve implantation. Korean Circulation Journal, 42(10), 652. https://doi.org/10.4070/kcj.2012.42.10.652